| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
79,620,000 |
| Market
Cap: |
12.77(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1604 - $0.1604 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 586 |
| Guru Rank Value : 3.2 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare diseases. Co.'s primary candidate is Diazoxide Choline Extended Release tablets (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,544,640 |
2,981,495 |
4,387,462 |
5,807,319 |
| Total Sell Value |
$173,528,326 |
$201,535,495 |
$268,405,086 |
$330,879,697 |
| Total People Sold |
8 |
8 |
8 |
8 |
| Total Sell Transactions |
11 |
20 |
47 |
74 |
| End Date |
2025-03-27 |
2024-12-24 |
2024-06-25 |
2023-06-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Volck Birgitte |
|
– • – |
2025-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,991 |
17,536 |
|
- |
|
| Pauls Matthew |
|
– • – |
2025-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,991 |
10,491 |
|
- |
|
| Bir Dawn Carter |
|
– • – |
2025-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,991 |
16,991 |
|
- |
|
| Harris William G |
|
– • – |
2025-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,991 |
19,392 |
|
- |
|
| Sinclair Andrew |
|
– • – |
2025-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,991 |
10,491 |
|
- |
|
| Hirano Patricia C |
SEE REMARKS |
• – – |
2025-04-01 |
4 |
AS |
$70.11 |
$265,156 |
D/D |
(3,782) |
27,036 |
|
- |
|
| Pauls Matthew |
|
– • – |
2025-03-28 |
4 |
S |
$71.55 |
$424,797 |
D/D |
(5,937) |
6,500 |
|
- |
|
| Pauls Matthew |
|
– • – |
2025-03-28 |
4 |
OE |
$4.60 |
$27,310 |
D/D |
5,937 |
12,437 |
|
- |
|
| Hirano Patricia C |
SEE REMARKS |
• – – |
2025-03-28 |
4 |
AS |
$67.46 |
$1,919,636 |
D/D |
(27,662) |
30,818 |
|
- |
|
| Hirano Patricia C |
SEE REMARKS |
• – – |
2025-03-28 |
4 |
OE |
$33.60 |
$90,418 |
D/D |
2,691 |
58,480 |
|
- |
|
| Vivo Opportunity Fund Holdings, L.p. |
10% Owner |
– – • |
2025-03-28 |
4 |
S |
$70.60 |
$23,549,124 |
I/I |
(333,557) |
4,458,294 |
|
- |
|
| Yen Kristen |
SEE REMARKS |
• – – |
2025-03-27 |
4 |
S |
$65.97 |
$6,376,789 |
D/D |
(95,500) |
28,143 |
|
- |
|
| Yen Kristen |
SEE REMARKS |
• – – |
2025-03-27 |
4 |
OE |
$2.41 |
$201,966 |
D/D |
40,638 |
101,774 |
|
- |
|
| Mackaness James H |
CHIEF FINANCIAL OFFICER |
• – – |
2025-03-27 |
4 |
S |
$65.97 |
$6,293,177 |
D/D |
(90,622) |
105,176 |
|
- |
|
| Mackaness James H |
CHIEF FINANCIAL OFFICER |
• – – |
2025-03-27 |
4 |
OE |
$2.41 |
$820,125 |
D/D |
70,000 |
175,176 |
|
- |
|
| Manning Meredith |
Chief Commercial Officer |
• – – |
2025-03-27 |
4 |
S |
$65.97 |
$3,044,343 |
D/D |
(45,249) |
45,351 |
|
- |
|
| Manning Meredith |
Chief Commercial Officer |
• – – |
2025-03-27 |
4 |
OE |
$46.31 |
$1,713,470 |
D/D |
37,000 |
82,351 |
|
- |
|
| Huang Michael F. |
Sr. VP of Clinical Development |
• – – |
2025-03-27 |
4 |
S |
$65.97 |
$1,013,627 |
D/D |
(14,583) |
36,817 |
|
- |
|
| Huang Michael F. |
Sr. VP of Clinical Development |
• – – |
2025-03-27 |
4 |
OE |
$21.93 |
$219,300 |
D/D |
10,000 |
46,817 |
|
- |
|
| Anish Bhatnagar |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-03-27 |
4 |
S |
$65.81 |
$47,271,960 |
D/D |
(699,095) |
577,076 |
|
- |
|
| Anish Bhatnagar |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-03-27 |
4 |
OE |
$2.41 |
$6,373,861 |
D/D |
523,809 |
1,100,885 |
|
- |
|
| Hirano Patricia C |
SEE REMARKS |
• – – |
2025-03-27 |
4 |
AS |
$65.97 |
$8,789,717 |
D/D |
(128,653) |
55,789 |
|
- |
|
| Hirano Patricia C |
SEE REMARKS |
• – – |
2025-03-27 |
4 |
OE |
$2.41 |
$518,557 |
D/D |
72,140 |
166,913 |
|
- |
|
| Vivo Opportunity Fund Holdings, L.p. |
10% Owner |
– – • |
2025-03-27 |
4 |
S |
$67.80 |
$74,580,000 |
I/I |
(1,100,000) |
4,791,851 |
|
- |
|
| Vivo Opportunity Fund Holdings, L.p. |
10% Owner |
– – • |
2025-03-26 |
4 |
S |
$65.80 |
$26,320,000 |
I/I |
(400,000) |
5,891,851 |
|
- |
|
450 Records found
|
|
Page 1 of 18 |
|
|
